Complement factor 5a as a therapeutic target

Woodruff, T.M., Proctor, L.M., Strachan, A.J. and Taylor, S.M. (2006) Complement factor 5a as a therapeutic target. Drugs of The Future, 31 4: 325-334. doi:10.1358/dof.2006.031.04.980656


Author Woodruff, T.M.
Proctor, L.M.
Strachan, A.J.
Taylor, S.M.
Title Complement factor 5a as a therapeutic target
Journal name Drugs of The Future   Check publisher's open access policy
ISSN 0377-8282
Publication date 2006-01-01
Sub-type Critical review of research, literature review, critical commentary
DOI 10.1358/dof.2006.031.04.980656
Volume 31
Issue 4
Start page 325
End page 334
Total pages 10
Place of publication Barcelona
Publisher Prous Science, Sa
Language eng
Subject C1
11 Medical and Health Sciences
Abstract The complement system is an innate immune defense mechanism that protects the host from infection and injury. Complement activation results in the formation of anaphylatoxins, including the biologically active protein C5a. This anaphylatoxin is a potent chemotactic agent for immune and inflammatory cells and induces cell activation. In situations of excessive or uncontrolled complement activation, the overproduction of C5a can cause deleterious effects to the host, and this process is implicated in the pathogenesis of numerous immunoinflammatory disease states, including rheumatoid arthritis, psoriasis, inflammatory bowel disease, ischemia-reperfusion injuries and others. The presence of C5a in a wide variety of condition's has prompted many groups to examine the potential of inhibiting this complement activation product, with the aim of controlling these diseases and reducing the pathologic process. However, to date there is no clinically available specific C5a inhibitor and development of this new drug class is still in a relatively early stage, although limited phase I and phase II human clinical trials have been undertaken in the last few years with selected agents. In this review, examination of the current evidence supporting a specific role of C5a in selected disease states and an overview of potential therapeutic C5a inhibitors will enable the critical evaluation of the potential for C5a as a therapeutic target.
Keyword Pharmacology & Pharmacy
C5a Receptor Antagonist
Ischemia-reperfusion Injury
Inflammatory-bowel-disease
Membrane Attack Complex
Reduces Infarct Size
Rheumatoid-arthritis
Myocardial-infarction
Anaphylatoxin C5a
Ischemia/reperfusion Injury
Experimental-models
Q-Index Code C1
Additional Notes This document is a journal review.

Document type: Journal Article
Sub-type: Critical review of research, literature review, critical commentary
Collections: Excellence in Research Australia (ERA) - Collection
2007 Higher Education Research Data Collection
School of Biomedical Sciences Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 7 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 7 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Wed, 15 Aug 2007, 18:33:03 EST